Hematologic Malignancy
Conditions
Interventions
Control group: conventional anti-tumor therapy without any preventive liver protection treatment:None
Observation group: conventional anti-tumor therapy + magnesium isoglycyrrhizinate preventive liver protection therapy:None
Sponsors
China Academy of Medical Sciences Blood Disease Hospital (China Academy of Medical Sciences Hematology Institute)
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Patients with hematological malignancies (including but not limited to lymphoma, myeloma, leukemia); 2. Age >= 18 years; 3. Patients with at least one new anti-tumor drug in the anti-tumor treatment regimen *; 4. The use of magnesium isoglycyrrhizinate to prevent liver injury treatment time is the first course of anti-tumor therapy on the day or before (magnesium isoglycyrrhizinate dose >= 150 mg/day, and medication duration >= 5 days); 5.TBiL <= 1.0 × ULN; ALT, AST <= 1.0 × ULN; ALP <= 1.0 × ULN before magnesium isoglycyrrhizinate prophylaxis;
Exclusion criteria
Exclusion criteria: 1.Patients using other types of hepatoprotective drugs except magnesium isoglycyrrhizinate (such as polyene phosphatidylcholine, reduced glutathione and tiopronin, etc.); 2. Patients with combined liver local radiotherapy; 3. Patients combined with cellular immunotherapy *; 4. Patients with hepatitis B or hepatitis C virus in a replicative state and requiring antiviral therapy; 5. Patients who lack key clinical data information such as liver function indicators and cannot make clinical judgment on the diagnosis of liver injury related to anti-tumor drugs; * Cellular immunotherapy includes cytokine-induced killer cell therapy, dendritic cell therapy, DC + CIK cell therapy, natural killer cell therapy, and DC ~ T cell therapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence and severity of liver injury within 21 days, 30 days and 60 days of magnesium isoglycyrrhizinate prophylaxis; | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety; | — |
Countries
China
Contacts
Public ContactErlie Jiang
China Academy of Medical Sciences Blood Disease Hospital (China Academy of Medical Sciences Hematology Institute)
Outcome results
None listed